Non classé
Annaida Technologies SA closes oversubscribed Pre-Series A
Annaida Technologies, a Vaud-based start-up company bringing magnetic resonance to the scale of cells, announces the successful closing of its oversubscribed Pre-Series A funding round. The round, led by HEMEX, saw the participation from existing investors including Zürcher Kantonalbank (ZKB), Excellis, EFI Lake Geneva Ventures, and members of Club degli Investitori through Simon…
Read MoreAB2 Bio & Nippon Shinyaku Partner on U.S. License for Tadekinig Alfa
AB2 Bio and Nippon Shinyaku Sign U.S. Licensing Agreement for Tadekinig Alfa to Treat Ultra-Rare Autoimmune Disease AB2 Bio Ltd., a Vaud-based biotech company specializing in therapies for severe hyperinflammatory diseases, has entered into a strategic agreement with Nippon Shinyaku, a leading Japanese pharmaceutical company, for the commercialization of its breakthrough treatment Tadekinig alfa…
Read MoreBioAlps Industry Award Nomination 2025
Merci de bien vouloir remplir ce formulaire pour indiquer l’entreprise que vous souhaitez nommer pour le BioAlps Industry Award 2025 qui sera remis le 11 novembre 2025 au Théâtre du Crochetan à Monthey lors du BioAlps Networking Day. Les nominations seront évaluées selon les critères suivants : impact économique, intégration dans le réseau, investissement, nombre…
Read MoreBIND 2025 – Submit your project
The applications are now closed.
Read MoreBioAlps Association Privacy Policy
BioAlps Association’s Privacy Statement: The purpose of this Privacy Policy is to inform you of the procedures regarding the collection, use and disclosure of information on the BioAlps website, including any mobile versions or related mobile applications, collectively called BioAlps Association Sites. 1. About BioAlps Association Founded in 2003, BioAlps Association empowers the…
Read MoreGeneral Terms and Conditions
General Terms and Conditions – BioAlps Association Use of material on this website Material and database on this website may be reproduced, made available or revised for derivative works on other websites or databases without express permission which can be obtained from contact@bioalps.org. You may link to the relevant page on this website…
Read MoreModerna plans to produce a RNA vaccine against RSV in Valais
Moderna, which developed one of the first messenger RNA vaccines against Covid-19, has disclosed positive preliminary results for a trial against the Respiratory Syncytial Virus (RSV), which causes bronchiolitis, in the elderly. The vaccine will be produced in Boston (USA) and in Visp (Switzerland) The phase 3 trial is being conducted in a double-blind…
Read MoreCafé Innovation | HUG | 5 April
Innovation Café, Tuesday 5 April , 2022 from 12:45 to 1:45 pm. Theme: “Personalized cancer immunotherapy in Geneva: from the laboratory to Phase II, the journey of MaxiVAX”. Presented by Pr Nicolas Mach, Oncology Department of the HUG & Faculty of Medicine of the University of Geneva, co-founder of the startup MaxiVAX. Where: Centre de…
Read MoreCHF 1 billion for Vaud-based start-ups
2021 was a record fundraising year for Swiss startups, according to the Swiss Venture Capital Report 2022. The covid 19 pandemic did not slow down investments in Switzerland. And companies in the canton of Vaud have been particularly fortunate. Vaud’s young tech firms pulled in CHF 604.6 million in venture capital. An additional CHF…
Read More